NEXGEL, INC. Overview
Pro stress-test →NEXGEL specializes in the development and manufacturing of advanced, high-water-content hydrogels for healthcare, medical device, cosmetic, and consumer wellness applications. The company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. In April 2026, NEXGEL completed the closing of its license and acquisition of a portfolio of commercial-stage regenerative biomaterials products from Celularity Inc.
Strategic Profile
Pro stress-test →With scalable infrastructure, proprietary intellectual property, and growing demand across multiple sectors, NEXGEL is well-positioned to lead innovation in topical delivery systems. The company generates revenue from branded over-the-counter (OTC), private label, and Contract Development and Manufacturing Organization (CDMO) channels, providing flexibility, scale, and reduced market dependence. The Celularity transaction establishes NEXGEL as an emerging platform in regenerative medicine through the formation of BioNX Surgical, a dedicated division focused on advanced biomaterials for tendon repair, soft tissue reconstruction, and bone regeneration.
Competitive Landscape
Pro stress-test →NEXGEL's proprietary hydrogels provide superior adhesion, breathability, and comfort for wound care, drug delivery, medical devices, and consumer health products. The company competes in wound care, regenerative biomaterials, and specialty OTC products with multi-channel distribution across clinical, professional, and consumer segments. Recent expansion into regenerative medicine through the BioNX Surgical division positions it to compete with larger medtech players and specialized biomaterials companies.
Industry Context
NEXGEL, INC. operates in Regenerative Medicine and Advanced Biomaterials.
Key facts
Founded: N/A · Headquarters: Langhorne, Pennsylvania · Employees: N/A · Revenue: ~$35M (pro forma post-Celularity) · Market cap: N/A